" there's another competing private company with an approved device that does the same thing luviva does"
If you're talking about Zilico's ZedScan, you're wrong. Have a nice day.
Inane ramblings that do not address the real overhang with current share price - the debt and the continuing conversions and selling by a hedge fund that is sucking every dime they can out of this company. But you think this is at $1.03 today because of comments made by someone on Facebook and a message board? Do you have any idea how foolish that sounds?
Share price is sitting at $1.06 because IMSC received a $162-million contract from a US government agency? Ridiculous. IMSC is burdened with toxic financing and is beholden to a parasite hedge fund that dumps shares with both hands into any positive news. Imo, these dirt/bags are probably trading both sides of every company they're involved with.
Trader who posts his stock picks on iHub. Just search iHub for "$heff" and you'll find his board. Enjoy the circa '97 spinning/flashing web graphics.
You have a lot of the $heff message board lemmings here that got into this and now they're all crying because they didn't get their 3% in two days and now they've lost their next car payment. GL.
The only thing taking the stock down since TSA approval is DMRJ dumping millions of shares. Have you looked at the A/D line since approval? Have a nice day.
Six pages of messages in a month? Have a nice day.
NORCROSS, Ga.--(BUSINESS WIRE)-- Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced the pricing of a public offering and the entry into definitive agreements with purchasers for the sale of approximately 16.8 million shares of its common stock, and warrants to purchase shares of its common stock, for gross proceeds to the Company (including non-cash extinguishment of debt) of approximately $3.8 million. The shares and warrants are being offered at a combined price of $0.225 per share. Each warrant will be exercisable for five years to purchase one half of a share of the Company's common stock at an exercise price of $0.225 per share.
The Company expects to use the cash proceeds to continue to seek FDA approval for LuViva, to repay certain bridge loans, and to support general working capital and operations. However, the Company will retain broad discretion over the use of the net proceeds and may use the money for other corporate purposes.
Olympus Securities, LLC is the sole placement agent for the offering, which is expected to close on or about December 1, 2014, subject to the satisfaction of customary closing conditions.
"man crush..." That's funny. No such crush here... Glanced at the other board, saw the familiar names. Didn't read much... As far as large orders, they won't mean much to the bottom line near term as we learned for the first time on the last CC that they are making $0 on device sales. I was blind-sided by that one, if Faupel ever said that I missed it. I think that's a ridiculous model for this kind of company. We need FDA approval and a partner right on the heels of that... Did you ever ask Cartwright what kind of feedback he's gotten from the board lately? From people like Imhoff who have staked a lot here?
Big Eddie, so that's where you and Seabiscuit have been hiding out. Don't find time to read a lot of message boards. As far as GTHP these days... As one of my teenage nephews likes to say, "I'm not feeling it" with GTHP lately. Not feeling anything good, anyway. I get the feeling we're about to get flushed with this offering and they're going to let a bottom feeding hedge in the door to boot. I bet the Turkish distributor is feeling shafted at this point with the .307 they paid. Cartwright is a good speaker but everything always takes longer than his original publicly stated timelines. The wait for this financing has been the worst. Hopefully - soon - he'll learn to stop throwing dates around when he really has no idea whether or not he can keep them. Good luck!
If this is Platinum they're getting in bed with, well, lookout below. At this point there are probably a lot of people just waiting for FDA approval to dump... Last 7 trading days:
Uh oh. I added some this morning also. I hope this turns out to be a case of great minds thinking alike and not a case of a dumb herd of cattle heading down the chute together. Good luck.
Sales: $262,000 or $22,000 less than their estimate from two days ago.
Interesting note re: Magna notes:
On November 6, 2014, Magna agreed to refrain from converting any portion of the Convertible Notes or selling any shares of the Company’s common stock until after November 21, 2014, in exchange for an acceleration of the scheduled increase in the conversion discount on the Initial Convertible Note from December 19, 2014 to November 21, 2014.
DMRJ owns the longs. Who do you think smashed the share price after QPL?
Recent Sales of Unregistered Securities
In April 2014 and September 2014, DMRJ converted $116,000 and $212,000, respectively, of the accrued interest owed by us under a promissory note into 1,450,000 and 2,650,000 shares, respectively, of our common stock, at an adjusted conversion price of $0.08 per share. The issuance of these securities to DMRJ is exempt from registration under the Securities Act of 1933, as amended, pursuant to an exemption provided by Section 3(a)(9) and/or Section 4(2) of the Securities Act.
Those weren't open market purchases.
Explanation of Responses:
1. Acquired from the Issuer in lieu of cash compensation for board and committee service during 3Q 2014.